23 Jul

How to price the IP rights underpinning disruptive biotech innovation

With Astellas, Roche and Celgene all spending big sums to acquire ground-breaking biotech outfits, Epsilon Economics’ Grace Park and Mohan Rao look at the best ways to get IP value for money in an ambitious market

Grace Park

Analyst | Epsilon Economics

Mohan Rao

CEO | Epsilon Economics